Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance
Authors
Keywords
-
Journal
Cancers
Volume 14, Issue 5, Pages 1321
Publisher
MDPI AG
Online
2022-03-07
DOI
10.3390/cancers14051321
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Distribution of KRASG12C Somatic Mutations across Race, Sex, and Cancer Type
- (2021) Amin H. Nassar et al. NEW ENGLAND JOURNAL OF MEDICINE
- 99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation
- (2021) G.J. Riely et al. Journal of Thoracic Oncology
- KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from the in vitro experiments
- (2021) Takamasa Koga et al. Journal of Thoracic Oncology
- Mechanisms of Resistance to KRASG12C-Targeted Therapy
- (2021) Neal S. Akhave et al. Cancer Discovery
- Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches
- (2021) M. Reck et al. ANNALS OF ONCOLOGY
- KRAS inhibitor-resistance in MET-amplified KRASG12C non-small cell lung cancer induced by RAS- and non-RAS-mediated cell signaling mechanisms
- (2021) Shinichiro Suzuki et al. CLINICAL CANCER RESEARCH
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation
- (2021) Ferdinandos Skoulidis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired Resistance to KRASG12C Inhibition in Cancer
- (2021) Mark M. Awad et al. NEW ENGLAND JOURNAL OF MEDICINE
- On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
- (2021) Colin R. Lindsay et al. LUNG CANCER
- Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
- (2021) Daolin Tang et al. Molecular Cancer
- Diverse alterations associated with resistance to KRAS(G12C) inhibition
- (2021) Yulei Zhao et al. NATURE
- Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
- (2021) Biagio Ricciuti et al. Journal of Thoracic Oncology
- Overcoming Adaptive Resistance to KRAS Inhibitors Through Vertical Pathway Targeting
- (2020) Rona Yaeger et al. CLINICAL CANCER RESEARCH
- Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
- (2020) Jenny Y. Xue et al. NATURE
- Resistance looms for KRASG12C inhibitors
- (2020) Aaron N. Hata et al. NATURE MEDICINE
- EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer
- (2020) Vito Amodio et al. Cancer Discovery
- RAS-targeted therapies: is the undruggable drugged?
- (2020) Amanda R. Moore et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients
- (2020) Dongsung Kim et al. CELL
- Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer
- (2020) Yuta Adachi et al. CLINICAL CANCER RESEARCH
- KRAS inhibition in non–small cell lung cancer: Past failures, new findings and upcoming challenges
- (2020) Francesco Passiglia et al. EUROPEAN JOURNAL OF CANCER
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
- (2020) David S. Hong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of immunotherapy and co-mutations on KRAS-mutant non- small cell lung cancer survival
- (2020) Idoroenyi Amanam et al. Journal of Thoracic Disease
- Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction
- (2019) Roman C. Hillig et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
- (2019) Arnaud Jeanson et al. Journal of Thoracic Oncology
- KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer
- (2019) Wenting Liao et al. CANCER CELL
- K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways
- (2019) Matthias Scheffler et al. Journal of Thoracic Oncology
- Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition
- (2019) Meagan B. Ryan et al. CLINICAL CANCER RESEARCH
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- (2019) Suresh S. Ramalingam et al. NEW ENGLAND JOURNAL OF MEDICINE
- KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis
- (2019) Dana Rabara et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
- (2019) Jill Hallin et al. Cancer Discovery
- KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy
- (2019) Ghimessy et al. Cancers
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Treating KRAS-mutant NSCLC: latest evidence and clinical consequences
- (2017) Pilar Garrido et al. Therapeutic Advances in Medical Oncology
- Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
- (2016) Zhong-Yi Dong et al. CLINICAL CANCER RESEARCH
- Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
- (2016) Fabrice Barlesi et al. LANCET
- Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
- (2016) Jonathan M. L. Ostrem et al. NATURE REVIEWS DRUG DISCOVERY
- The 2015 World Health Organization Classification of Lung Tumors
- (2015) William D. Travis et al. Journal of Thoracic Oncology
- Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart
- (2015) William D. Travis et al. Journal of Thoracic Oncology
- KRAS Mutations as Prognostic and Predictive Markers in Non–Small Cell Lung Cancer
- (2013) Petra Martin et al. Journal of Thoracic Oncology
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers
- (2012) S. Dogan et al. CLINICAL CANCER RESEARCH
- KRAS Mutations in Lung Cancer
- (2012) Niki Karachaliou et al. Clinical Lung Cancer
- KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies
- (2009) Chen Mao et al. LUNG CANCER
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells
- (2009) Junichi Soh et al. PLoS One
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation